Alan S. Wayne, MD

Pediatrician-in-Chief and Senior Vice President of Academic Affairs

Pasadena Guild Chair

Children’s Hospital Los Angeles

Chair, Department of Pediatrics

Professor of Pediatrics and Medicine

Keck School of Medicine of USC

Alan S. Wayne, MD, leads the implementation of the Department’s strategic and operating plans; recruitment, development and retention of faculty at CHLA; as well as oversees the hospital’s educational and research advancements, including those performed at The Saban Research Institute, CHLA's freestanding research facility dedicated to finding new treatments and cures for the most complex childhood diseases. Dr. Wayne also serves on CHLA’s Board of Directors. Dr. Wayne's prior roles at CHLA have included Chief, Division of Hematology-Oncology and Director, Cancer and Blood Disease Institute. Prior to joining CHLA/USC in 2013, Dr. Wayne served for 14 years as Clinical Director of the Pediatric Oncology Branch of the National Cancer Institute at the National Institutes of Health.

Clinical Interests

Hematologic malignancies; hematopoietic stem cell transplantation and cellular therapy; cancer immunotherapy

Bench-to-bedside development of targeted, immune-based and cellular therapies for leukemias and lymphomas, with a primary focus on relapsed/refractory acute lymphoblastic leukemia

Biology, prevention and treatment of relapse of hematologic malignancies after allogeneic hematopoietic stem cell transplantation

Education

Medical School

Honors Program in Medical Education, Northwestern University Medical School

Internship

Pediatrics, Department of Medicine, Boston Children’s Hospital, Harvard Medical School

Residency

Pediatrics, Department of Medicine, Boston Children’s Hospital, Harvard Medical School

Chief Residency, Pediatrics, Department of Medicine, Boston Children’s Hospital, Harvard Medical School

Fellowship

Pediatric Hematology-Oncology, Boston Children’s Hospital; Dana-Farber Cancer Institute

Accomplishments

Certifications

American Board of Pediatrics, Sub-board of Pediatric Hematology-Oncology

Professional Memberships

Society for Pediatric Research
American Pediatric Society
American Society of Hematology
American Society of Pediatric Hematology/Oncology
Children’s Oncology Group

Awards

Top Doctors, Los Angeles Business Journal, 2020
Top Doctors, Los Angeles Magazine, 2018-19
Top Doctors, Pasadena Magazine, 2015-19
Medical Advancement Award, T.J. Martell Foundation, 2018
Healing Award, Tower Cancer Research Foundation, 2018
The Best Doctors in America, 1995-2015
National Institutes of Health Director’s Award, National Institutes of Health, 2007
The Sidney Farber Award, 1988

Areas of Focus

Pediatric hematology-oncology

Publications

PubMed Link

Publications on PubMed

Research

Dr. Wayne’s primary research efforts are directed towards the development of new treatment approaches for leukemias and lymphomas with a focus on relapsed/refractory acute lymphoblastic leukemia. He develops and leads collaborative laboratory, translational and clinical investigations, including bench-to-bedside development of targeted, immune-based and cellular therapies. He serves as the Medical Director of the Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium, a multinational clinical trials group that conducts Phase I and II trials. He is also an international leader in the area of post-transplant relapse of hematologic malignancies, with the primary aim to study the biology, prevention and treatment of relapse after hematopoietic stem cell transplant.

Research Studies

UCART19-Paediatric Acute Lymphoblastic Leukaemia (PALL) Study

UCART19 is intended to treat CD19-positive B lymphoid malignancies in paediatric and adult populations.

Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium (TACL) Marqibo® ALL study

This study aims to evaluate the side effects (good and bad) of giving Vincristine Suflate Liposome Infection (also known as Marqibo®) - a drug approved for leukemia treatment in adults but that is experimental in children - with other standard chemotherapy drugs and to measure how effective the combination is at treating children and young adults with leukemia that has come back after initial treatment.